Texas Pain Relief Group PLLC
Texas Pain Relief Group PLLC was paid $507K by Medicaid between Mar 2020 and Dec 2024, across 25 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 52% of everything it billed.
HURST, TX 76054
Next to other Pain Medicine (Physical Medicine & Rehabilitation) Physician providers in Texas
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 1,091 | $1K | |
| 2021 | 3,288 | $34K | |
| 2022 | 5,464 | $128K | |
| 2023 | 6,560 | $194K | |
| 2024incomplete | 5,100 | $149K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 52% | 11,229 | 10,038 | $263K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 15% | 3,736 | 3,539 | $76K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 14% | 3,842 | 3,532 | $73K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 9.3% | 510 | 477 | $47K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 5.5% | 540 | 517 | $28K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1.0% | 128 | 125 | $5K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | <1% | 32 | 32 | $2K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 34 | 33 | $2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 54 | 52 | $2K |
| 83992 | <1% | 161 | 158 | $1K | |
| 99205 | Prolong outpt/office vis | <1% | 13 | 13 | $1K |
| 80356 | <1% | 162 | 159 | $961.00 |
13 more codes
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Charles K Friedman DO PA | St Petersburg, FL | $2.96M |
| West Park Surgery Center LLC | Pinellas Park, FL | $2.37M |
| Florida Pain Relief Group PLLC | Tampa, FL | $1.90M |
| Medical Tox Labs, LLC | Tampa, FL | $655K |
| Physician Partners of America Crna Operations LLC | Hurst, TX | $349K |
| Medhat F. Mikhael, M.D., INC | Fountain Valley, CA | $341K |
| Sun City Center Ambulatory Surgery Center, LLC | Ruskin, FL | $274K |
| Medical Dna Labs, LLC | Tampa, FL | $107K |
| Richard L Smith MD PA | Orlando, FL | $74K |
| Merritt Island Outpatient Surgery Center, LLC | Merritt Island, FL | $15K |
| Hurst Ambulatory Surgery Center, LLC | Hurst, TX | $275.62 |
| Pain Institute of Tampa Bay, PLC | Tampa, FL | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.